Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats

References

• Abe M, Toyohara T, Ishii A, et al. (2010). The HMG-CoA reductase inhibitor pravastatin stimulates insulin secretion through organic anion transporter polypeptides. Drug Metab Pharmacokinet 25:274–82
   PubMed Web of Science ®Google Scholar
• An L, Ravindran PP, Renukunta S, Denduluri S. (2013). Co-medication of pravastatin and paroxetine – a categorical study. J Clin Pharmacol 53 :1212–19
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. (2001). The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24:1069–78
   PubMed Web of Science ®Google Scholar
• Arakawa H, Shirasaka Y, Haga M, et al. (2012). Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5. Biopharm Drug Dispos 33:332–41
   PubMed Web of Science ®Google Scholar
• Araki K, Masaki T, Katsuragi I, et al. (2008). Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice. Obesity (Silver Spring) 16:2068–73
   PubMed Web of Science ®Google Scholar
• Besson A, Haddjeri N, Blier P, de Montigny C. (2000). Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 10:177–88
   PubMed Web of Science ®Google Scholar
• Bourin M, Chue P, Guillon Y. (2001). Paroxetine: a review. CNS Drug Rev 7:25–47
   PubMedGoogle Scholar
• Chen GM, Hu N, Liu L, et al. (2011). Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection. Xenobiotica 41:494–500
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–96
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Sattar N, et al. (2001). Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357–62
   PubMed Web of Science ®Google Scholar
• Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. (2004). Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 58:614–18
   PubMed Web of Science ®Google Scholar
• Gui C, Wahlgren B, Lushington GH, Hagenbuch B. (2009). Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17beta-glucuronide transport. Pharmacol Res 60:50–6
   PubMed Web of Science ®Google Scholar
• Gulseren L, Gulseren S, Hekimsoy Z, Mete L. (2005). Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 36:159–65
   PubMed Web of Science ®Google Scholar
• Hu N, Xie S, Liu L, et al. (2010). Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 39:419–25
   PubMed Web of Science ®Google Scholar
• Ishigami M, Tokui T, Komai T, et al. (1995). Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharm Res 12:1741–5
   PubMed Web of Science ®Google Scholar
• Jerrell JM. (2010). Neuroendocrine-related adverse events associated with antidepressant treatment in children and adolescents. CNS Neurosci Ther 16:83–90
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705
   PubMed Web of Science ®Google Scholar
• Khoza S, Barner JC. (2011). Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm 33:484–92
   PubMed Web of Science ®Google Scholar
• Klein C, Pillot T, Chambaz J, Drouet B. (2003). Determination of plasma membrane fluidity with a fluorescent analogue of sphingomyelin by FRAP measurement using a standard confocal microscope. Brain Res Brain Res Protoc 11:46–51
   PubMedGoogle Scholar
• Kobayashi T, Matsumoto T, Kamata K. (2000). Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br J Pharmacol 131:231–8
   PubMed Web of Science ®Google Scholar
• Komai T, Shigehara E, Tokui T, et al. (1992). Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43:667–70
   PubMed Web of Science ®Google Scholar
• Li F, Zhang M, Xu D, et al. (2014). Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure. Acta Pharmacol Sin 35:792–805
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang M, Hu MY, et al. (2013). Increased glucagon-like peptide-1 secretion may be involved in antidiabetic effects of ginsenosides. J Endocrinol 217:185–96
   PubMed Web of Science ®Google Scholar
• Liu H, Liu L, Li J, et al. (2012). Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus. Drug Metab Dispos 40:1104–12
   PubMed Web of Science ®Google Scholar
• Maeda T, Takahashi K, Ohtsu N, et al. (2007). Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm 4:85–94
   PubMed Web of Science ®Google Scholar
• Masmoudi J, Damak R, Zouari H, et al. (2013). Prevalence and impact of anxiety and depression on type 2 diabetes in Tunisian patients over sixty years old. Depress Res Treat 2013:341782
   PubMedGoogle Scholar
• McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. (2006). The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 5:157–68
   PubMed Web of Science ®Google Scholar
• Moreno G, Mangione CM. (2013). Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002–2012 literature review. J Am Geriatr Soc 61:2027–37
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, et al. (2005). Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–78
   PubMed Web of Science ®Google Scholar
• Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. (2003). Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract 4:7
   PubMedGoogle Scholar
• Roy T, Lloyd CE. (2012). Epidemiology of depression and diabetes: a systematic review. J Affect Disord 142:S8–21
   PubMed Web of Science ®Google Scholar
• Smoller JW, Allison M, Cochrane BB, et al. (2009). Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med 169:2128–39
   PubMed Web of Science ®Google Scholar
• Tamai I. (2012). Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev 64:508–14
   PubMed Web of Science ®Google Scholar
• Tatonetti NP, Denny JC, Murphy SN, et al. (2011). Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 90:133–42
   PubMed Web of Science ®Google Scholar
• Tokui T, Nakai D, Nakagomi R, et al. (1999). Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 16:904–8
   PubMed Web of Science ®Google Scholar
• Transon C, Leemann T, Dayer P. (1996). In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50:209–15
   PubMed Web of Science ®Google Scholar
• van Dooren FE, Nefs G, Schram MT, et al. (2013). Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 8:e57058
   PubMed Web of Science ®Google Scholar
• Varma MV, Lin J, Bi YA, et al. (2013). Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 41:966–74
   PubMed Web of Science ®Google Scholar
• White RW, Tatonetti NP, Shah NH, et al. (2013). Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc 20:404–8
   PubMed Web of Science ®Google Scholar
• Winocour PD, Bryszewska M, Watala C, et al. (1990). Reduced membrane fluidity in platelets from diabetic patients. Diabetes 39:241–4
   PubMed Web of Science ®Google Scholar
• Yguerabide J, Schmidt JA, Yguerabide EE. (1982). Lateral mobility in membranes as detected by fluorescence recovery after photobleaching. Biophys J 40:69–75
   PubMed Web of Science ®Google Scholar
• Zimmermann U, Kraus T, Himmerich H, et al. (2003). Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37:193–220
   PubMed Web of Science ®Google Scholar
• Zuberi SI, Syed EU, Bhatti JA. (2011). Association of depression with treatment outcomes in type 2 diabetes mellitus: a cross-sectional study from Karachi, Pakistan. BMC Psychiatry 11:27
   PubMed Web of Science ®Google Scholar